Notably, in NSCLC and other solid tumors, several KRAS G12C inhibitors are being combined with immune checkpoint inhibitors (ICI), SHP2 inhibitors, EGFR inhibitors, and bevacizumab in clinical trials22,29. Here, EGFR is linked to non-small cell lung carcinoma.